Eli Lilly and Co. reports it has begun clinical trials for testing therapies for COVID-19. The drug company said it has entered into an agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to study baricitinib. The study will investigate baricitinib as a potential treatment for hospitalized patients diagnosed with COVID-19, beginning this month in the U.S. with a planned expansion to additional sites including Europe and Asia. Results are expected within the next two months.
Long Island Doctors See Improvements with COVID-19 Patients
Dr. Ryan Saadi, of Quantaira Health, partnered with Dr. Muhammad Alam and Dr. Imtiaz Ahmad at Plainview Hospital using the much-talked-about hydroxychloroquine combined with the antibiotic doxycycline. The combination therapy was administered to dozens of high-risk COVID-19 patients at three long term care facilities on Long Island. They say most of those patients have now fully recovered.
Two Thirds of COVID-19 Patients Improve after Gilead Drug
More than two-thirds of severely ill COVID-19 patients saw their condition improve after treatment with remdesivir, an experimental drug being developed by Gilead Sciences Inc., according to new data based on patient observation. The analysis, published on Friday by the New England Journal of Medicine, does not detail what other treatments the 61 hospitalized patients were given and data on eight of them were not included — in one case because of a dosing error.